NCCN Receives $2.2 Million in Research Funding from Astellas and Medivation to Study Enzalutamide in Solid Tumors
The NCCN Oncology Research Program (ORP) received a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to facilitate studies of enzalutamide in bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.
FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the cl...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Endometrial Cancer | Funding | Grants | Ovarian Cancer | Ovaries | Pharmaceuticals | Prostate Cancer | Study